Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota IntroductionThis study was designed to identify a group of bacteria in the human gut microbiota with specific effects on PD-1-based immunotherapy for patients with non-small cell lung cancer (NSCLC).MethodsThe study was performed in patients with advanced NSCLC, who received PD-1 monoclonal antibody (mAb) treatment for 6 months after one or several prior therapies. The combination of blood immune-related factors of the participants and their 16S rRNA gene sequencing from fecal samples at baseline was used to investigate the diversity and composition of the gut microbiota. The differences in relative abundance of gut microbiota at the genus level were compared, and the relation to blood immune-related factors was assessed using Spearman’s rank correlation coefficient analysis.ResultsThe 16S rRNA gene sequencing showed a clear difference in the diversity and composition of the gut microbiota between groups with stable disease (SD) and progressive disease (PD). A comparison of differences in relative abundance at the genus level showed that the relative abundance of Escherichia-Shigella, Akkermansia and Olsenella in the SD group was significantly higher than that in the PD group. The SD group had significantly higher interleukin-12 (IL-12) and interferon γ (IFN-γ) levels than the PD group. Interestingly, the numbers of white blood cells and sorted cells in the SD group were higher than those in the PD group. Spearman’s rank correlation coefficient analysis showed that Escherichia-Shigella was positively correlated with IL-12, IFN-γ and basophils. Akkermansia was positively correlated with monocytes.ConclusionThe response to PD-1-based immunotherapy in patients with NSCLC is affected by the diversity and composition of the gut microbiota. Escherichia-Shigella and Akkermansia may have specific effects on PD-1 inhibitory immunotherapy for NSCLC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/response-to-pd-1-based-immunotherapy-for-non-small-cell-lung-cancer-QnkEaVdEo6
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00171-3
Publisher site
See Article on Publisher Site

Abstract

IntroductionThis study was designed to identify a group of bacteria in the human gut microbiota with specific effects on PD-1-based immunotherapy for patients with non-small cell lung cancer (NSCLC).MethodsThe study was performed in patients with advanced NSCLC, who received PD-1 monoclonal antibody (mAb) treatment for 6 months after one or several prior therapies. The combination of blood immune-related factors of the participants and their 16S rRNA gene sequencing from fecal samples at baseline was used to investigate the diversity and composition of the gut microbiota. The differences in relative abundance of gut microbiota at the genus level were compared, and the relation to blood immune-related factors was assessed using Spearman’s rank correlation coefficient analysis.ResultsThe 16S rRNA gene sequencing showed a clear difference in the diversity and composition of the gut microbiota between groups with stable disease (SD) and progressive disease (PD). A comparison of differences in relative abundance at the genus level showed that the relative abundance of Escherichia-Shigella, Akkermansia and Olsenella in the SD group was significantly higher than that in the PD group. The SD group had significantly higher interleukin-12 (IL-12) and interferon γ (IFN-γ) levels than the PD group. Interestingly, the numbers of white blood cells and sorted cells in the SD group were higher than those in the PD group. Spearman’s rank correlation coefficient analysis showed that Escherichia-Shigella was positively correlated with IL-12, IFN-γ and basophils. Akkermansia was positively correlated with monocytes.ConclusionThe response to PD-1-based immunotherapy in patients with NSCLC is affected by the diversity and composition of the gut microbiota. Escherichia-Shigella and Akkermansia may have specific effects on PD-1 inhibitory immunotherapy for NSCLC.

Journal

Oncology and Therapy – Springer Journals

Published: Dec 1, 2021

Keywords: NSCLC; Gut microbiome; PD-1; Immunotherapy

References

  • The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
    Derosa, L
  • The biology and management of non-small cell lung cancer
    Herbst, RS; Morgensztern, D; Boshoff, C
  • Lung cancer: a wily genetic opponent
    Hsu, PP; Shaw, AT
  • Immunotherapy in non-small cell lung cancer: facts and hopes
    Doroshow, DB
  • Neoadjuvant PD-1 blockade in resectable lung cancer
    Forde, PM
  • Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC): a review on toxicity profile and its management
    Sgambato, A
  • PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions
    Xia, L; Liu, Y; Wang, Y
  • A conserved dendritic-cell regulatory program limits antitumour immunity
    Maier, B
  • Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
    Brueckl, WM; Ficker, JH; Zeitler, G
  • The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer
    Hakozaki, T
  • The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy
    Gopalakrishnan, V
  • Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
    Gopalakrishnan, V
  • Gut microbiome and cancer immunotherapy
    Li, W
  • Microbial biomarkers for immune checkpoint blockade therapy against cancer
    Adachi, K; Tamada, K
  • Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
    Routy, B
  • The intestinal microbiome influences checkpoint blockade
    Sears, CL; Pardoll, DM
  • Recognition of enteroinvasive Escherichia coli and Shigella flexneri by dendritic cells: distinct dendritic cell activation states
    Moreno, AC